Showing 581-590 of 10527 results for "".
Two Investment Options with Upside Potential and Downside Protection: Equity-indexed Life Policies and Structured Notes
https://practicaldermatology.com/topics/practice-management/two-investment-options-with-upside-potential-and-downside-protection-equity-indexed-life-policies-and-structured-notes/23332/Options provide valuable components of a physician’s overall portfolio.Keloids: To Cut or Not to Cut
https://practicaldermatology.com/topics/skin-cancer-photoprotection/keloids-to-cut-or-not-to-cut/19987/When treating keloids, ask patients what they want to achieve. Are they hoping to decrease itch or pain? Do they want to flatten or soften the appearance of a keloid? Hilary Baldwin, MD reviews her approach to deciding whether to remove a keloid surgically as well as other treatment options. Plus, sDerm Insider: Navigating Office Politics
https://practicaldermatology.com/topics/practice-management/derm-insider-navigating-office-politics/18993/In this edition of Derm Insider, host Neal Bhatia, MD speaks with practice management experts about the complex inner workings of an office environment, as well as the role of physicians in managing precarious situations regarding employees. Offering advice for maneuvering these situations, guests SLight & Bright: A new treatment to illuminate your practice
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/light-bright-a-new-treatment-to-illuminate-your-practice/19746/Join Matthew Mahlberg, MD as he introduces the new Light & Bright treatment. Using the patented Ellipse IPL and Frax 1550 technologies on the Nordlys system, the Light & Bright treatment reduces pigmentation & redness and improves textural irregularities. Hear the results of a clinical sDupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sActinic Keratosis: Therapy Overview
https://practicaldermatology.com/topics/skin-cancer-photoprotection/actinic-keratosis-therapy-overview/19732/Joel Cohen, MD interviews George Martin, MD about the latest developments in actinic keratosis. Dr. Martin said he is eagerly awaiting regulatory review of tirbanibulin, which showed promising results in clinical trials. The two also discuss practical tips and nuances of using 5FU in practice. *Be sPhysician Spotlight
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight/21164/"Ask Me Anything" Mentorship Session With Dr. Tina Bhutani
https://practicaldermatology.com/programs/practical-dermatology/ask-me-anything-mentorship-session-with-dr-tina-bhutani/39251/Tina Bhutani, MD, MAS, FAAD, describes her career journey and answers various questions from YoungMD Connect members. YoungMD Connect is an editorially independent platform made possible by industry sponsorships. We would like to thank our silver platform sponsor, Incyte, and bronze sponsor, AlmiralThe Value of Radiation as an Option for BCC and SCC
https://practicaldermatology.com/issues/may-june-2025/the-value-of-radiation-as-an-option-for-bcc-and-scc/35919/The Skin Cancer Foundation calls Mohs micrographic surgery the gold standard for treating basal cell carcinomas and squamous cell carcinomas.SCALE 2024: Listen as Dr. Joel Cohen and Dr. Suneel Chilukuri on Microwave Therapy
https://practicaldermatology.com/error/404/Suneel Chilukuri, MD, discusses the various applications of microwave therapy, including non-melanoma skin cancer, with Joel Cohen, MD, at Music City SCALE.